|
|
|
Volumn 23, Issue 6 SUPPL. 16, 1996, Pages 11-15
|
|
Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: A University of Colorado Cancer Center study
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
ETOPOSIDE;
GRANULOCYTE COLONY STIMULATING FACTOR;
PACLITAXEL;
ADULT;
ADVANCED CANCER;
BLOOD TOXICITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
FEMALE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
LUNG SMALL CELL CANCER;
MALE;
MAXIMUM PERMISSIBLE DOSE;
NAUSEA;
NEUTROPENIA;
ORAL DRUG ADMINISTRATION;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
VOMITING;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, SMALL CELL;
CISPLATIN;
DRUG ADMINISTRATION SCHEDULE;
ETOPOSIDE;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
NEUTROPENIA;
PACLITAXEL;
SURVIVAL RATE;
THROMBOCYTOPENIA;
|
|
EID: 0030463011
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (4)
|
|
References (11)
|